94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Oncol.
Sec. Cancer Molecular Targets and Therapeutics
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1548399
Prognostic value of CA125 in diffuse large B-cell lymphoma
Provisionally accepted- 1 Department of Oncology,Nantong Tumor Hospital, Nantong, Jiangsu Province, China
- 2 School of Medicine, Nantong University, Nantong, Jiangsu Province, China
- 3 Nantong Rich Hospital, Nantong, Jiangsu Province, China
- 4 Department of Pathology, Nantong Tumor Hospital, Nanjing, Jiangsu Province, China
BACKGROUND: Carbohydrate antigen 125 (CA125) is one of the most commonly used tumor biomarker for evaluating the prognosis of solid neoplasms. It has been reported that serum CA125 is correlated with the prognosis of non-Hodgkin's lymphoma. The objective of this study is to explore the clinical value of CA125 in diffuse large B-cell lymphoma (DLBCL). METHODS: We retrospectively analyzed the clinical and pathological data in a cohort of 315 newly diagnosed patients with DLBCL. In our case, the correlations between serum CA125 and clinicopathological parameters were analyzed. Kaplan-Meier survival curve and cox proportional hazards model were applied to evaluate the prognosis. The expression of CA125 in DLBCL paraffin tissues was detected by immunohistochemistry. RESULTS: 82 patients (26%) with DLBCL had elevated serum CA125 levels at diagnosis. Elevated serum CA125 levels were associated with poor performances status, greater than or equal to 2 Extranodal sites, advanced Ann Arbor stage (Ⅲ-Ⅳ), presence of B symptoms, presence of bulky mass, presence of effusion, intermediate/ high-risk International Prognostic Index (IPI), elevated lactate dehydrogenase levels and reduced albumin levels. Patients with elevated serum CA125 levels at diagnosis had shorter progression free survival (PFS) and overall survival (OS). Multivariate analysis revealed that serum CA125, cell of origin, IPI score and albumin were independent prognostic factors for OS and PFS. In addition, the results of the immunohistochemistry indicated that none of the 82 DLBCL paraffin tissues expressed CA125 in lymphoma cells and the surrounding microenvironment cells. CONCLUSIONS: Serum CA125 detected at the initial diagnosis is a strong predictor of prognosis in patients with DLBCL.
Keywords: Carbohydrate antigen 125, Diffuse large B-cell lymphoma, biomarker, prognisis, Overall survival, Progression free survival
Received: 19 Dec 2024; Accepted: 12 Feb 2025.
Copyright: © 2025 Xu, Zhang, Jiang, Chen, Xu, Ge and Miao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Xiaohong Xu, Department of Oncology,Nantong Tumor Hospital, Nantong, 226000, Jiangsu Province, China
Xiaobing Miao, Department of Pathology, Nantong Tumor Hospital, Nanjing, Jiangsu Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.